[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353762-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353762-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","high-throughput-screening-of-drug-libraries-identifies-a-new-synergistic-drug-combination-for-the-treatment-of-retinoblastoma","High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma","","Retinoblastoma (RB) management relies on multi-agent chemotherapy and ocular therapies, yet chemoresistance, relapse, and systemic and eye toxicities drive the need for alternative drugs. Limited pediatric-cancer resources further constrain discovery and development. A drug repurposing approach was used to find candidates that are cytotoxic and selective for human RB Y79 cells in vitro and in an orthotopic xenograft mouse model. High-throughput screening showed gemcitabine as highly cytotoxic in Y79 cells with potential synergy to thermotherapy and minimal effects on RPE-1 cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/high-throughput-screening-of-drug-libraries-identifies-a-new-synergistic-drug-combination-for-the-treatment-of-retinoblastoma/353762/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/high-throughput-screening-of-drug-libraries-identifies-a-new-synergistic-drug-combination-for-the-treatment-of-retinoblastoma/353762.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are alternative drugs needed for retinoblastoma treatment?","Question",{"text":63,"@type":64},"Current RB therapies face chemoresistance and relapse, along with systemic and ocular toxicities. This motivates the search for safer or more effective drug options.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What strategy was used to identify potential drug candidates?",{"text":68,"@type":64},"A drug repurposing strategy was used to select candidates that are cytotoxic and selective for human RB Y79 cells in vitro and effective in an orthotopic xenograft mouse model in vivo.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main results involving gemcitabine?",{"text":72,"@type":64},"High-throughput screening showed gemcitabine’s strong cytotoxicity in Y79 cells, including potential synergy with thermotherapy. The gemcitabine–carboplatin combination outperformed the clinically used etoposide–carboplatin regimen, with improved eye survival and reduced optic nerve tumor invasion in xenografts.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353762,1790439073,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","OPEN ACCESS  \nCitation: Tseng P-J, Sinenko IL, Chambon M, Banfi D, Zugbi S, Cancela MB, et al. (2026) High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma. PLoS One 21(2): e0339334. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0339334](journal.pone.0339334)  \nEditor: Irina V. Lebedeva, Weill Cornell Medicine, UNITED STATES OF AMERICA Received: June 26, 2024  \nAccepted: December 5, 2025  \nPublished: February 25, 2026  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0339334  \nCopyright: © 2026 Tseng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nHigh-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma  \nPo-Jen Tseng1☯, Irina L. Sinenko1,2☯, Marc Chambon3, Damiano Banfi3,  \nSantiago Zugbi4,5, María Belén Cancela4,5, Kseniya A. Glinkina1, Gerardo Turcatti3, Christina Stathopoulos2, Paula Schaiquevich4,5*, Francis L. Munier2*, Paul J. Dyson1*  \n1 Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland, 2 Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland, 3 Biomolecular Screening Facility, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland, 4 Unit of Innovative Treatments, Hospital de Pediatría JPGarrahan, Buenos Aires, Argentina, 5 National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina  \n☯ These authors contributed equally to this work.  \n* [paula.schaiquevich@gmail.com](paula.schaiquevich@gmail.com) (PS); [francis.munier@fa2.ch](francis.munier@fa2.ch) (FM); [paul.dyson@epfl.ch](paul.dyson@epfl.ch) (PD)  \nAbstract  \nRetinoblastoma (RB) management often involves the combination of chemotherapeutic agents (e.g. , carboplatin and etoposide) and techniques (e.g. , chemotherapy and thermotherapy) . Chemoresistance and relapse, as well as systemic and ocular toxicities of current retinoblastoma chemotherapeutics necessitate the implementation of alternative drugs. Fewer resources and concern for pediatric cancer hinder drug discovery and development in an effective way. To overcome the obstacle, a drug repurposing strategy without intuition was adopted to identify promising drug candidates that are both cytotoxic and selective towards human RB Y79 cells in vitro and an orthotopic xenograft mice model in vivo. By using high-throughput screening, gemcitabine demonstrated high cytotoxicity in Y79 cells, also potentially synergizing with thermotherapy, with minimal impact on a human retinal pigment epithelial RPE-1 cells. Furthermore, the synergistic effect of gemcitabine with carboplatin is superior to the clinically used combination of etoposide with carboplatin. Efficacy studies in orthotopic xenografts showed significant eye survival advantages after intravitreal gemcitabine administration or the combination of intravitreal gemcitabine with systemic carboplatin compared to relevant controls. Importantly, the combination resulted in lower tumor invasion in the optic nerves of the xenografts. Since gemcitabine is an FDA-approved chemotherapeutic agent, already used to treat other pediatric cancers, it could be repurposed to RB treatment alone or in combination with carboplatin, and potentially combined with thermotherapy, providing the basis for an alternative and improved treatment option for RB patients.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0","cbCaieeYN86v2nIJ","https://ap.wps.com/l/cbCaieeYN86v2nIJ","pdf",2287453,"English","# Abstract\n## Background and rationale\n## Drug repurposing and screening approach\n## Key findings on gemcitabine synergy","[{\"question\":\"Why are alternative drugs needed for retinoblastoma treatment?\",\"answer\":\"Current RB therapies face chemoresistance and relapse, along with systemic and ocular toxicities. This motivates the search for safer or more effective drug options.\"},{\"question\":\"What strategy was used to identify potential drug candidates?\",\"answer\":\"A drug repurposing strategy was used to select candidates that are cytotoxic and selective for human RB Y79 cells in vitro and effective in an orthotopic xenograft mouse model in vivo.\"},{\"question\":\"What were the main results involving gemcitabine?\",\"answer\":\"High-throughput screening showed gemcitabine’s strong cytotoxicity in Y79 cells, including potential synergy with thermotherapy. The gemcitabine–carboplatin combination outperformed the clinically used etoposide–carboplatin regimen, with improved eye survival and reduced optic nerve tumor invasion in xenografts.\"}]","High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma | PDF",1790107105,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38941d03cff6d1569dc897e07693e217.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dbb0120263c9ed62aa5dec3f1268b9e.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/627dd03307edb5420dc2a608810f3904.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f9799c9dce13158cf1a0b2c4cefad99.webp",980,1268]